Personalized medicine is reaching geroscience in a meaningful way, and PROMETHEUS represents one of the more structured attempts to operationalize that idea in a clinical setting. Rather than treating aging as a uniform process, this protocol treats biological aging patterns as individually variable — a concept with real implications for how middle-aged and older adults might eventually be counseled about healthspan interventions.
The PROMETHEUS feasibility trial enrolled 20 middle-aged to older participants in an 8-week multimodal protocol developed as part of the XPRIZE Healthspan competition. All participants received a foundational layer of interventions: sleep and dietary guidance, supervised exercise incorporating dual-task cognitive-physical exergaming, motivational interviewing, and cognitive behavioral therapy. On top of this, a nutraceutical stack — whey protein, creatine, and fucoidan — was universally applied. The genuinely novel element is the augmented, personalized layer: participants were stratified by "gerotypes" reflecting individual aging trajectories rather than chronological age. Based on baseline muscle mass, peak oxygen uptake (VO2peak), and cognitive performance, some received urolithin A, nicotinamide mononucleotide (NMN), and/or a multivitamin-multimineral formulation. Mid-trial assessments allowed dose escalation and the potential addition of ergothioneine for participants showing insufficient cognitive improvement. Primary outcomes span muscle strength and mass, immune function, and cognitive performance.
The protocol is ambitious, but several caveats warrant attention. Twenty participants is a very small sample for a feasibility study, limiting statistical power and generalizability. The 8-week window is likely insufficient to detect meaningful longevity-relevant changes in biological aging biomarkers. The compound-stacking design — combining exercise, behavioral therapy, dietary changes, and multiple nutraceuticals simultaneously — makes it nearly impossible to attribute any observed effects to specific components. Urolithin A and NMN individually carry a growing but still incomplete human evidence base, and ergothioneine's cognitive effects remain exploratory. That said, this protocol's gerotype-stratified adaptive design is conceptually ahead of most aging trials, and the feasibility data, if published, could meaningfully inform the architecture of larger, better-powered studies.